Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Equity

Summit Therapeutics (SMMT) Invested Capital (2018 - 2025)

Summit Therapeutics' Invested Capital history spans 8 years, with the latest figure at $192.3 million for Q3 2025.

  • For Q3 2025, Invested Capital fell 56.1% year-over-year to $192.3 million; the TTM value through Dec 2025 reached $33.5 million, down 91.37%, while the annual FY2024 figure was $388.7 million, 400.37% up from the prior year.
  • Invested Capital reached $192.3 million in Q3 2025 per SMMT's latest filing, down from $259.4 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $437.9 million in Q3 2024 to a low of $44.2 million in Q1 2024.
  • Average Invested Capital over 5 years is $159.9 million, with a median of $119.6 million recorded in 2023.
  • Peak YoY movement for Invested Capital: crashed 66.88% in 2024, then surged 678.85% in 2025.
  • A 5-year view of Invested Capital shows it stood at $83.3 million in 2021, then skyrocketed by 52.07% to $126.7 million in 2022, then plummeted by 38.66% to $77.7 million in 2023, then soared by 400.37% to $388.7 million in 2024, then crashed by 50.54% to $192.3 million in 2025.
  • Per Business Quant, the three most recent readings for SMMT's Invested Capital are $192.3 million (Q3 2025), $259.4 million (Q2 2025), and $344.3 million (Q1 2025).